Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Rapid-acting antidepressants
Jeffrey M. Witkin, Anna Martin, Lalit K. Golani, et al.
Advances in pharmacology (2019), pp. 47-96
Closed Access | Times Cited: 61

Showing 1-25 of 61 citing articles:

Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine
Kenji Hashimoto
Biochemical Pharmacology (2020) Vol. 177, pp. 113935-113935
Open Access | Times Cited: 185
Anhedonia as a central factor in depression: Neural mechanisms revealed from preclinical to clinical evidence
Shijing Wang, Francesco Leri, Sakina J. Rizvi
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2021) Vol. 110, pp. 110289-110289
Closed Access | Times Cited: 108
Psychedelic-Induced Neural Plasticity: A Comprehensive Review and a Discussion of Clinical Implications
Francesco Weiss, Anna Magnesa, Matteo Gambini, et al.
Brain Sciences (2025) Vol. 15, Iss. 2, pp. 117-117
Open Access | Times Cited: 4
Depression: Biological markers and treatment
Gordana Nedić Erjavec, Marina Šagud, Matea Nikolac Perković, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2020) Vol. 105, pp. 110139-110139
Closed Access | Times Cited: 84
Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression
Susan Ling, Felicia Ceban, Leanna M.W. Lui, et al.
CNS Drugs (2021) Vol. 36, Iss. 1, pp. 17-30
Closed Access | Times Cited: 79
GABAkines – Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors
Rok Cerne, Arnold S. Lippa, Michael M. Poe, et al.
Pharmacology & Therapeutics (2021) Vol. 234, pp. 108035-108035
Open Access | Times Cited: 71
Novel drug developmental strategies for treatment‐resistant depression
Éva Borbély, Mária Simon, Eberhard Fuchs, et al.
British Journal of Pharmacology (2021) Vol. 179, Iss. 6, pp. 1146-1186
Open Access | Times Cited: 65
Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression
Yating Wang, Xiaole Wang, Sitong Feng, et al.
Pharmacological Research (2021) Vol. 171, pp. 105761-105761
Closed Access | Times Cited: 56
Discovering the Potential Mechanisms of Medicinal Mushrooms Antidepressant Activity: A Review
Jan Lazur, Kamil Hnatyk, Katarzyna Kała, et al.
Antioxidants (2023) Vol. 12, Iss. 3, pp. 623-623
Open Access | Times Cited: 34
(R)-(-)-Ketamine: The Promise of a Novel Treatment for Psychiatric and Neurological Disorders
Hana Shafique, Julie Demers, Julia Biesiada, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 12, pp. 6804-6804
Open Access | Times Cited: 9
Ketamine induces rapid antidepressant effects via the autophagy-NLRP3 inflammasome pathway
Dongbin Lyu, Fan Wang, Mengke Zhang, et al.
Psychopharmacology (2022) Vol. 239, Iss. 10, pp. 3201-3212
Closed Access | Times Cited: 34
Positive AMPA receptor modulation in the treatment of neuropsychiatric disorders: A long and winding road
Bashkim Kadriu, Laura Musazzi, Jenessa N. Johnston, et al.
Drug Discovery Today (2021) Vol. 26, Iss. 12, pp. 2816-2838
Open Access | Times Cited: 39
Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry
Hitoshi Sakurai, Kengo Yonezawa, Hideaki Tani, et al.
Pharmacopsychiatry (2022) Vol. 55, Iss. 04, pp. 193-202
Open Access | Times Cited: 22
Amplification of the therapeutic potential of AMPA receptor potentiators from the nootropic era to today
Daniel P. Radin, Arnold S. Lippa, Sabhya Rana, et al.
Pharmacology Biochemistry and Behavior (2025) Vol. 248, pp. 173967-173967
Closed Access
mGlu2/3 receptor antagonism: A mechanism to induce rapid antidepressant effects without ketamine-associated side-effects
Jeffrey M. Witkin
Pharmacology Biochemistry and Behavior (2020) Vol. 190, pp. 172854-172854
Closed Access | Times Cited: 33
Diversity of AMPA Receptor Ligands: Chemotypes, Binding Modes, Mechanisms of Action, and Therapeutic Effects
Elena A. Golubeva, Mstislav I. Lavrov, Eugene V. Radchenko, et al.
Biomolecules (2022) Vol. 13, Iss. 1, pp. 56-56
Open Access | Times Cited: 20
Clinical pharmacological innovation in the treatment of depression
Jeffrey M. Witkin, Lalit K. Golani, Jodi L. Smith
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 4, pp. 349-362
Closed Access | Times Cited: 12
Chaperone Sigma1R and Antidepressant Effect
М. В. Воронин, Yulia V. Vakhitova, С. Б. Середенин
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 19, pp. 7088-7088
Open Access | Times Cited: 29
Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism
Andrzej Pilc, Agata Machaczka, Paweł Kawalec, et al.
Expert Opinion on Drug Discovery (2022) Vol. 17, Iss. 10, pp. 1131-1146
Closed Access | Times Cited: 16
Subanesthetic dose of S-ketamine improved cognitive dysfunction via the inhibition of hippocampal astrocytosis in a mouse model of post-stroke chronic stress
Limin Zhang, Zhi‐You Wu, Jizhen Liu, et al.
Journal of Psychiatric Research (2022) Vol. 158, pp. 1-14
Closed Access | Times Cited: 16
Cyclooxygenase-2 inhibitors alleviated depressive and anxious-like behaviors in mice exposed to lipopolysaccharide: Involvement of oxidative stress and neuroinflammation
Daniel Moreira Alves da Silva, Iardja Stéfane Lopes Sales, João Victor Souza Oliveira, et al.
Pharmacology Biochemistry and Behavior (2024) Vol. 240, pp. 173778-173778
Closed Access | Times Cited: 3
R-(−)-ketamine modifies behavioral effects of morphine predicting efficacy as a novel therapy for opioid use disorder1
Jeffrey M. Witkin, Jay Kranzler, Kyle Kaniecki, et al.
Pharmacology Biochemistry and Behavior (2020) Vol. 194, pp. 172927-172927
Closed Access | Times Cited: 25
Repurposing of Drugs–The Ketamine Story
Joydip Das
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 22, pp. 13514-13525
Closed Access | Times Cited: 24
Neural plasticity and depression treatment
Yubing Wang, Ning‐Ning Song, Yu‐Qiang Ding, et al.
IBRO Neuroscience Reports (2022) Vol. 14, pp. 160-184
Open Access | Times Cited: 15
Sleep deprivation alleviates depression-like behaviors in mice via inhibiting immune and inflammatory pathways and improving neuroplasticity
Shuxiang Shi, Mengke Zhang, Weijie Xie, et al.
Journal of Affective Disorders (2023) Vol. 340, pp. 100-112
Closed Access | Times Cited: 8
Page 1 - Next Page

Scroll to top